2023 Fiscal Year Annual Research Report
Oral nanoparticle formulations for allergy treatment via efficient induction of immune tolerance
| Project/Area Number |
22KJ2442
|
|---|
| Allocation Type | Multi-year Fund |
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
李 晋廷 九州大学, システム生命科学府, 特別研究員(DC2)
|
|---|
| Project Period (FY) |
2023-03-08 – 2024-03-31
|
| Keywords | allergy treatment / nanoparticle / tolerance immunity / DDS |
|---|
| Outline of Annual Research Achievements |
In the current year, my research focusing on the development of nanoparticles inducing immune tolerance for allergy treatment has made significant progress. Herein, I present an overview of my research achievements for this year:
1. Background: The number of allergy patients is on the rise. Despite immunotherapy being the only curative treatment for allergies, its high incidence of side effects and low efficacy over a treatment period of more than three years have rendered the therapy less than satisfactory. Therefore, the development of a safe and efficient treatment method has become urgent. 2. Preparation: Traditional treatment methods involve the direct administration of antigens to patients, leading to the side effects. To address this issue, I encapsulated the antigen with hydrogel nanoparticles (NP) to prevent side effects. Additionally, I modified the NP with targeting ligands to DC to enhance treatment efficiency. As results, the size of NP was adjusted to 200 nm. 3. In Vitro: NP with DC-targeting ligands significantly improved the DC uptake efficiency and increased the levels of IL-10 released by DCs, indicating their significant anti-inflammatory capabilities. 4. In Vivo: Regarding safety, NP exhibited significantly reduced binding affinity with IgE. Furthermore, repeated subcutaneous injections of NP did not induce the production of anti-drug antibodies, such as IgG and IgM. More, NP showed significant therapeutic effects on allergic model mice by decreasing IgE and the number of eosinophils.
|
